ArticleInternational journal of clinical practice2017
Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
Article in International journal of clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04807920 (Intravesical OnabotulinumtoxinA Injection at the Time of Prolapse Surgery for the Treatment of Overactive Bladder Syndrome), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravesical OnabotulinumtoxinA Injection at the Time of Prolapse Surgery for the Treatment of Overactive Bladder Syndrome: a Randomized Controlled Trial
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?International urogynecology journal · 2021Pooled it
- Pooled it
- Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.Female pelvic medicine & reconstructive surgery · 2021Trial
- Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.Advances in therapy · 2026Review
- Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.Advances in therapy · 2024Article
- Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).Advances in therapy · 2024Observational
- Predictors of non-persistence in women with overactive bladder syndrome.Scientific reports · 2024Article
- Percutaneous Tibial Nerve Stimulation in the Treatment of Refractory Idiopathic Overactive Bladder Syndrome: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.BMC urology · 2023Article
- Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.Neurourology and urodynamics · 2022Article
- Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.Lower urinary tract symptoms · 2021Article
- Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review.Current urology · 2021Review
- Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.Neurourology and urodynamics · 2020Article
- Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.International urology and nephrology · 2020Article
- Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study.Drugs - real world outcomes · 2020Article
- The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.Drugs & aging · 2019Observational
- Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.Lower urinary tract symptoms · 2019Article
- Initial clinical experience with selective bladder denervation for refractory overactive bladder.Neurourology and urodynamics · 2019Article
- The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.Therapeutic advances in urology · 2018Review
- Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.International urology and nephrology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdherence and persistence rates of anticholinergic (ACH) therapies have been well described. To date, few studies describe these metrics for mirabegron in patients with overactive bladder.
methodsThis retrospective analysis of MarketScan
resultsThe mean age of mirabegron users (n = 4037) was 67 years and 43% were ACH naïve while the mean age of ACH users was 62 years (n = 67,943). Over the 12-month follow-up period, 44% of patients treated with mirabegron and 31% of patients treated with ACH were adherent to their indexed medications. Treatment failure was 81% for mirabegron and 88% for ACH. Most mirabegron treatment failures were because of treatment discontinuation (67%) versus switching to ACH therapy (14%). The ACH discontinuation rate was 84% and treatment switching rate was 4%. The mean (standard deviation) time to treatment failure was 143 (130) days for mirabegron and 69 (69) days for ACH. Adherence and persistence patterns were similar in the sensitivity analysis using a ≥ 45-day supply gap threshold.
conclusionsThis real-world study demonstrated low adherence and persistence to mirabegron similar to ACH therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.